Topline data were announced from a phase 3 trial evaluating gefurulimab in adults with anti-acetylcholine receptor antibody-positive generalised myasthenia gravis.

DEAR DR. ROACH: My husband woke up with double vision about three weeks ago. It appears that his left eye is turned inward ...

An optometrist has prescribed prism glasses, which help a little. He’s been wearing an eye patch to drive short distances.

Results from the Phase III PREVAIL trial (NCT05556096) of gefurulimab demonstrated a statistically significant and clinically ...

AstraZeneca (AZN) stock is in focus as the company's experimental drug gefurulimab for generalized myasthenia gravis hits ...

AstraZeneca's gefurulimab showed clinical benefits and favorable safety in Phase 3 trial for adults with anti-AChR ...

AstraZeneca (LSE:AZN) announced promising trial results for gefurulimab, a potential new treatment for generalized myasthenia ...

The company didn’t share specific data for the molecule, gefurulimab, but said it hit all endpoints in the Phase III PREVAIL ...

Dear Dr. Roach: My husband woke up with double vision about three weeks ago. It appears that his left eye is turned inward and does not move with his right eye. He's had a prescription for prednisone ...

Baron Funds, an investment management company, released its “Baron Health Care Fund” second-quarter 2025 investor letter. A ...

AstraZeneca’s investigational therapy gefurulimab has delivered positive results in the pivotal Phase III PREVAIL trial for ...

Miriam Freimer, MD, clinical professor of neurology at The Ohio State University Wexner Medical Center, reflects on how findings from the RAISE-XT trial potentially translate to real-world practice ...